Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Future Market Size Estimation For The Nasal Spray Influenza Vaccine Market Covering 2025–2034?
The nasal spray influenza vaccine market size has expanded rapidly in recent years. This market is projected to increase from $1.31 billion in 2024 to $1.48 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.2%. The expansion during the historical period can be attributed to enhanced vaccine accessibility, growing awareness regarding flu prevention, an increasing focus on pediatric vaccination, rising vaccination rates, and a growing preference for needle-free vaccines.
The nasal spray influenza vaccine market is projected for substantial expansion over the next few years, with its valuation anticipated to reach $2.38 billion by 2029, achieving a compound annual growth rate (CAGR) of 12.7%. This forecasted growth is primarily fueled by an increasing demand for convenient immunization options, a rise in seasonal influenza occurrences, enhanced government initiatives and support, the expected growth in geriatric and high-risk populations, and wider adoption within healthcare settings. Key trends expected in this period include advancements in vaccine delivery systems, the integration of mucosal immunity strategies, technological progress in viral vector platforms, improvements in cold-chain technology, and the incorporation of mRNA technology.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24326&type=smp
What Are The Drivers Pushing New Developments In The Nasal Spray Influenza Vaccine Market?
The rising occurrence of influenza is anticipated to drive the expansion of the nasal spray influenza vaccine market in the future. Influenza, a highly transmissible viral infection, primarily impacts the respiratory system, leading to symptoms like fever, coughing, sore throat, muscle pain, and tiredness. This growing prevalence of influenza is mainly attributed to the frequent genetic changes in the influenza virus, allowing it to bypass current immunity and disseminate quickly through communities. The nasal spray influenza vaccine offers protection from influenza by introducing a weakened version of the virus directly into the nasal passages, thereby triggering an immune reaction at the virus’s typical entry point into the body. For example, in June 2024, data from the UK Health Security Agency, a UK-based government body, indicated that from week 40 of 2022 to week 15 of 2023, 1,681 confirmed critical care admissions linked to influenza were documented by 108 NHS trusts in England. In contrast, the previous season recorded merely 182 admissions reported by 114 trusts, which then rose to 316 admissions by week 39 of 2022. Consequently, the rising incidence of influenza is fueling the expansion of the nasal spray influenza vaccine market.
What Are The Primary Types Of Segments Analyzed In The Nasal Spray Influenza Vaccine Market?
The nasal spray influenza vaccinemarket covered in this report is segmented –
1) By Type: Live Attenuated Influenza Vaccine (LAIV); Inactivated Influenza Vaccine
2) By Administration Method: Single-Dose Administration; Multi-Dose Administration
3) By Age Group: Pediatric; Adult; Geriatric
4) By Distribution Channel: Hospitals; Clinics; Pharmacies; Online Stores; Other Distribution Channels
5) By End User: Healthcare Providers; Individuals; Government Health Departments; Pharmaceutical Companies
Subsegments:
1) By Live Attenuated Influenza Vaccine (LAIV): Trivalent Live Attenuated Influenza Vaccine (Trivalent LAIV); Quadrivalent Live Attenuated Influenza Vaccine (Quadrivalent LAIV)
2) By Inactivated Influenza Vaccine: Whole Virus Inactivated Vaccine; Split Virus Inactivated Vaccine; Subunit Inactivated Vaccine; Adjuvanted Inactivated Vaccine; High-Dose Inactivated Vaccine
How Are Trends Influencing The Nasal Spray Influenza Vaccine Market?
Major companies in the nasal spray influenza vaccine market are prioritizing the development of innovative formulations, such as the live attenuated influenza vaccine, to improve immune response and patient compliance. A live attenuated influenza vaccine (LAIV) is composed of live, weakened influenza viruses that work to prevent influenza by stimulating the immune system to produce antibodies, thereby providing protection without causing the illness, and by offering a more comprehensive immune response through both local and systemic immunity, which enhances the body’s ability to defend against future flu infections. As an illustration, in September 2024, AstraZeneca Plc, a UK-based pharmaceutical industry company, obtained approval from the U.S. Food and Drug Administration (FDA) for FluMist, a live attenuated influenza vaccine (LAIV), to be self-administered by adults up to 49 years of age or administered by caregivers to children aged 2 to 17 years, making it the first and only influenza vaccine approved for self- or caregiver-administration in the United States. This approval was granted following comprehensive usability studies which demonstrated individuals’ capacity to correctly self-administer the vaccine, with 100% of participants successfully delivering a full dose as instructed.
Who Are The Top Performing Companies In The Nasal Spray Influenza Vaccine Market In Recent Years?
Major companies operating in the nasal spray influenza vaccine market are Sanofi Pasteur SA, AstraZeneca PLC, GSK plc, Moderna Inc., CSL Limited, Sinovac Biotech Ltd., Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Beijing Wantai Biological Pharmacy Enterprise Co. Ltd., NPO Microgen JSC, Changchun BCHT Biotechnology Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., BioDiem Ltd, Starpharma Holdings Limited, Codagenix Inc., Nobilon International B.V., KM Biologics Co. Ltd., Altimmune Inc., Mylab Discovery Solutions Private Limited
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/nasal-spray-influenza-vaccine-global-market-report
Which Geographies Are Emerging As Strong Markets For The Nasal Spray Influenza Vaccine Industry?
North America was the largest region in the nasal spray influenza vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal spray influenza vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Nasal Spray Influenza Vaccine Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24326&type=smp
Browse Through More Reports Similar to the Global Nasal Spray Influenza Vaccine Market 2025, By The Business Research Company
Drug Delivery Devices Market 2025
https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-market
High Flow Nasal Cannula Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/high-flow-nasal-cannula-global-market-report
Inhalation And Nasal Spray Generic Drugs Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model